TY - JOUR T1 - Effective Contact Tracing for COVID-19: A Systematic Review JF - medRxiv DO - 10.1101/2020.07.23.20160234 SP - 2020.07.23.20160234 AU - Carl-Etienne Juneau AU - Anne-Sara Briand AU - Tomas Pueyo AU - Pablo Collazzo AU - Louise Potvin Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/07/25/2020.07.23.20160234.abstract N2 - Background Contact tracing is commonly recommended to control outbreaks of COVID-19, but its effectiveness is unclear. This systematic review aimed to examine contact tracing effectiveness in the context of COVID-19.Methods Following PRISMA guidelines, MEDLINE, Embase, Global Health, and All EBM Reviews were searched using a range of terms related to contact tracing for COVID-19. Articles were included if they reported on the ability of contact tracing to slow or stop the spread of COVID-19 or on characteristics of effective tracing efforts. Two investigators screened all studies.Results A total of 32 articles were found. All were observational or modelling studies, so the quality of the evidence was low. Observational studies (n=14) all reported that contact tracing (alone or in combination with other interventions) was associated with better control of COVID-19. Results of modelling studies (n=18) depended on their assumptions. Under assumptions of prompt and thorough tracing with no further transmission, they found that contact tracing could stop an outbreak (e.g. by reducing the reproduction number from 2.2 to 0.57) or that it could reduce infections (e.g. by 24%-71% with a mobile tracing app). Under assumptions of slower, less efficient tracing, modelling studies suggested that tracing could slow, but not stop COVID-19.Conclusions Observational and modelling studies suggest that contact tracing is associated with better control of COVID-19. Its effectiveness likely depends on a number of factors, including how many and how fast contacts are traced and quarantined, and how effective quarantines are at preventing further transmission. A cautious interpretation suggests that to stop the spread of COVID-19, public health practitioners have 2-3 days from the time a new case develops symptoms to isolate the case and quarantine at least 80% of its contacts, and that once isolated, cases and contacts should infect zero new cases. Less efficient tracing may slow, but not stop, the spread of COVID-19. Inefficient tracing (with delays of 4-5+ days or less than 60% of contacts quarantined with no further transmission) may not contribute meaningfully to control of COVID-19.Funding LP holds the Canada Research Chair in Community Approaches and Health Inequalities (CRC 950-232541). This funding source had no role in the design, conduct, or reporting of the study.Competing interests CEJ has contractual agreements with the Centre intégré universitaire de santé et de services sociaux du Centre-Sud-de-l’Île-de-Montréal and is founder of Dr. Muscle and the COVID-19 Science Updates (https://covid1.substack.com/).Registration PROSPERO CRD42020198462Competing Interest StatementCEJ has contractual agreements with the Centre integre universitaire de sante et de services sociaux du Centre-Sud-de-l'Ile-de-Montreal and is founder of Dr. Muscle (https://dr-muscle.com/) and the COVID-19 Science Updates (https://covid1.substack.com/).Funding StatementLP holds the Canada Research Chair in Community Approaches and Health Inequalities (CRC 950-232541). This funding source had no role in the design, conduct, or reporting of the study.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Systematic reviewAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data available upon request. ER -